We applied the Lasso fitted 27-antigen model on test results for sera from breast and ovarian cancer and neuroblastoma patients (Table 2) to determine the BARD1 lung cancer test specificity in respect of possible cross-reactivity with other cancers. This evidence concerns the gene BARD1 and ovarian cancer.